Published in Neuro Oncol on September 07, 2012
The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther (2015) 0.89
A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival. Neuro Oncol (2013) 0.87
TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells. Oncotarget (2016) 0.85
Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human. EMBO Rep (2014) 0.81
Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae. J Neurosurg (2015) 0.78
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Front Oncol (2014) 0.76
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Signalling downstream of activated mammalian Notch. Nature (1995) 11.08
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36
A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell (2000) 5.53
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
A simplified spectrophotometric determination of ester groups in lipids. Biochim Biophys Acta (1959) 4.38
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
Radial glial identity is promoted by Notch1 signaling in the murine forebrain. Neuron (2000) 3.70
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell (2009) 3.38
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem (2003) 2.22
Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol (2006) 2.09
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood (2002) 2.03
Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proc Natl Acad Sci U S A (2007) 1.98
Notch signaling in development and disease. Semin Cancer Biol (2004) 1.97
Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol (2009) 1.97
Smooth Muscle alpha-actin is a direct target of Notch/CSL. Circ Res (2006) 1.90
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther (2010) 1.62
Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc (2007) 1.60
Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development (1994) 1.54
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene (2005) 1.43
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res (2005) 1.42
ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int Immunol (2008) 1.38
AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia (2003) 1.30
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res (2008) 1.22
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res (2010) 1.14
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci (2005) 1.10
Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol (2008) 1.05
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett (2008) 0.97
Keeping mammalian mutation load in check: regulation of the activity of error-prone DNA polymerases by p53 and p21. Cell Cycle (2006) 0.96
YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol (2009) 0.91
Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol (2010) 0.88
Trafficking, acidification, and growth factor signaling. Sci Signal (2010) 0.87
The Ku antigen-recombination signal-binding protein Jkappa complex binds to the nuclear factor-kappaB p50 promoter and acts as a positive regulator of p50 expression in human gastric cancer cells. J Biol Chem (2003) 0.86
Preparation and antitumor activity of o-palmitoyldextran phosphates, o-palmitoyldextrans, and dextran phosphate. Carbohydr Res (1977) 0.81
Determining the LIF-sensitive period for implantation using a LIF-receptor antagonist. Reproduction (2009) 0.81
Expression of the IL-6 family cytokines in human brain tumors. Int J Oncol (2001) 0.79
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A (2005) 1.77
Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol (2003) 1.69
Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc (2007) 1.60
Labelling of cells with quantum dots. Nanotechnology (2005) 1.57
Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma. PLoS Comput Biol (2012) 1.54
A novel transfecting peptide comprising a tetrameric nuclear localization sequence. J Mol Med (Berl) (2003) 1.48
Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med (2004) 1.48
Percutaneous endoscopic gastrostomy in children on peritoneal dialysis. Perit Dial Int (2006) 1.47
Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int (2004) 1.46
Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem (2003) 1.45
Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations. Nephrol Dial Transplant (2012) 1.44
Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release (2009) 1.42
Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol (2010) 1.41
Changes in 11beta-hydroxysteroid dehydrogenase type 2 expression in a low-protein rat model of intrauterine growth restriction. Nephrol Dial Transplant (2010) 1.40
Magnetofection--a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther (2003) 1.29
Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol (2013) 1.29
Type 3 deiodinase, a thyroid-hormone-inactivating enzyme, controls survival and maturation of cone photoreceptors. J Neurosci (2010) 1.26
Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res (2003) 1.20
Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv Drug Deliv Rev (2011) 1.19
Nanoparticles as a novel class of autophagy activators. Autophagy (2007) 1.17
Nonviral vector loaded collagen sponges for sustained gene delivery in vitro and in vivo. J Gene Med (2002) 1.15
Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res (2005) 1.09
Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res (2004) 1.09
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res (2014) 1.07
Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med (2004) 1.06
Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem (2011) 1.04
Retarded developmental expression and patterning of retinal cone opsins in hypothyroid mice. Endocrinology (2008) 1.03
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther (2009) 0.99
siRNA delivery by magnetofection. Curr Opin Mol Ther (2008) 0.98
Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res (2007) 0.95
Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res (2004) 0.94
Aerosolized nanogram quantities of plasmid DNA mediate highly efficient gene delivery to mouse airway epithelium. Mol Ther (2005) 0.94
Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation (2004) 0.92
Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol (2009) 0.92
Monomolecular assembly of siRNA and poly(ethylene glycol)-peptide copolymers. Biomacromolecules (2008) 0.91
Inhibition of TGF-β signaling and decreased apoptosis in IUGR-associated lung disease in rats. PLoS One (2011) 0.91
The implications of fetal programming of glomerular number and renal function. J Mol Med (Berl) (2009) 0.91
Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther (2009) 0.90
A fibrin glue composition as carrier for nucleic acid vectors. Pharm Res (2008) 0.90
Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet (2002) 0.90
Genuine DNA/polyethylenimine (PEI) complexes improve transfection properties and cell survival. J Drug Target (2004) 0.89
Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med (2008) 0.87
Gene silencing mediated by magnetic lipospheres tagged with small interfering RNA. Nano Lett (2010) 0.87
A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival. Neuro Oncol (2013) 0.87
Angiogenic inhibition in high-grade gliomas: past, present and future. Expert Rev Neurother (2012) 0.86
Primary focal segmental glomerulosclerosis--long-term outcome after pediatric renal transplantation. Pediatr Transplant (2005) 0.86
Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clin Cancer Res (2013) 0.86
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol (2014) 0.85
Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes. Biomaterials (2011) 0.85
Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm (2010) 0.85
Fetal programming of renal function. Pediatr Nephrol (2011) 0.85
Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Clin Pract Oncol (2008) 0.84
Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria. Pharm Res (2012) 0.84
Early and late postnatal myocardial and vascular changes in a protein restriction rat model of intrauterine growth restriction. PLoS One (2011) 0.83
Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant (2006) 0.83
Low nephron number--a new cardiovascular risk factor in children? Pediatr Nephrol (2004) 0.83
Magnetic field-controlled gene expression in encapsulated cells. J Control Release (2011) 0.83
Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood (2011) 0.83
Magnetofection: the use of magnetic nanoparticles for nucleic acid delivery. Cold Spring Harb Protoc (2009) 0.83
Fetal programming of gene expression in growth-restricted rats depends on the cause of low birth weight. Endocrinology (2011) 0.83
In vivo analysis of retroviral gene transfer to chondrocytes within collagen scaffolds for the treatment of osteochondral defects. Biomaterials (2007) 0.83
Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation (2003) 0.83
Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung. Pharm Res (2012) 0.82
Optimization of magnetic nanoparticle-assisted lentiviral gene transfer. Pharm Res (2012) 0.82
Targeted endothelial gene delivery by ultrasonic destruction of magnetic microbubbles carrying lentiviral vectors. Pharm Res (2012) 0.82
A strategy to establish a gene-activated matrix on titanium using gene vectors protected in a polylactide coating. Biomaterials (2011) 0.81
Nucleic acid delivery to magnetically-labeled cells in a 2D array and at the luminal surface of cell culture tube and their detection by MRI. J Biomed Nanotechnol (2009) 0.81
Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. Neuro Oncol (2014) 0.81
The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials (2009) 0.81
Non-viral VEGF(165) gene therapy--magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an oversized skin flap model. J Cell Mol Med (2008) 0.80
Nanomagnetic activation as a way to control the efficacy of nucleic acid delivery. Pharm Res (2014) 0.80
Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery. Pediatrics (2006) 0.80
Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. Vet Immunol Immunopathol (2011) 0.80
Aerosol gene delivery to the murine lung is mouse strain dependent. J Mol Med (Berl) (2006) 0.79
Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation (2007) 0.79
Nanomedicine: Silence the target. Nat Nanotechnol (2009) 0.79
Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacol Rep (2010) 0.79